Vikas Lifecare Limited has secured shareholder approval for three key resolutions through a postal ballot process that concluded on May 15, 2026. The company sought consent for alterations to its Articles of Association, the issuance of fully convertible warrants, and an increase in authorized share capital. The scrutinizer, M/s Avinash K & Company, submitted the report confirming the results on May 18, 2026.

Voting Outcome

The resolutions were passed with the requisite majority as per Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A total of 8,21,216 shareholders were eligible to participate in the e-voting process, which commenced on April 16, 2026. The results indicate a high level of approval across all proposals.

Resolution Details

The first resolution sought the alteration of the Articles of Association of the Company. This special resolution received 99.75% of the total votes cast in favour. The second resolution, also a special resolution, authorized the issuance of up to 61,90,62,500 fully convertible warrants on a preferential basis to persons belonging to the promoter, promoter group, and non-promoter public category. This proposal was approved with 99.73% of the votes in favour.

The third resolution, an ordinary resolution regarding the increase in authorized share capital and the consequent amendment to the capital clause of the Memorandum of Association, was passed with 99.84% of the votes in favour.

Voting Summary

The detailed voting results show that the Promoter and Promoter Group cast 26,33,73,880 votes in favour of all resolutions, with zero votes against. Public shareholders also supported the resolutions, with dissenting votes ranging from 0.16% to 0.27% of the total votes polled.

Vikas Lifecare Limited published newspaper advertisements of its unaudited financial results for the quarter ended September 30, 2025, and quarter and nine months ended December 31, 2025, in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The company submitted copies of newspaper advertisements to both National Stock Exchange of India Limited and BSE Limited on April 25, 2026. The financial results were published in Financial Express (English Edition) and Jansatta (Hindi Edition) newspapers dated April 24 & 25, 2026.

Q3FY26 Financial Performance

The company's unaudited consolidated and standalone financial results show mixed performance across different quarters. The results were approved by the Board of Directors at their meeting held on April 21, 2026, following review by the Audit Committee.

Nine Months Performance

For the nine months ended December 31, 2025, the company reported total income of ₹46,560.00 lakhs on consolidated basis and ₹45,949.12 lakhs on standalone basis. The company maintained its paid-up equity share capital at ₹18,598.36 lakhs with face value of ₹1 each.

Board Approval and Documentation

The financial results received statutory auditor's limited review and were digitally signed by Managing Director Sundeep Kumar Dhawan (DIN: 09508137). The company's registered office is located at Vikas House, 3, Arihant Nagar, Punjabi Bagh West, New Delhi - 110026.

Manufacturing Facilities

Vikas Lifecare operates two manufacturing facilities - Factory I at G-83, Vigyan Nagar, RIICO Industrial Area, Shahjahanpur, Rajasthan, and Factory II at Plot No. 193, Baikampady, Mangaluru, Karnataka. The company maintains compliance with all regulatory requirements through proper documentation and timely submissions to stock exchanges.